The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. In formula I, the variables have the following meanings: m is 1 or 2, n is 1 or 2, A is selected from the group consisting of CH2, CH2CH2, CHFCH2 and CF2CH2, R1 is hydrogen or C1-C3-alkyl, R2 is selected from the group consisting of hydrogen, and fluorine, R3a is selected from the group consisting of hydrogen and methyl, R3b is selected from the group consisting of hydrogen and methyl, R4 is branched C4-C6 alkyl or branched fluorinated C4-C6 alkyl, and R5 is an oxygen containing radical such as C1-C2-alkoxy-C1-C4-alkyl, fluorinated C1-C2-alkoxy-C1-C4-alkyl, hydroxy-C1-C4-alkyl, fluorinated hydroxy-C1-C4-alkyl, oxetanyl, fluorinated oxetanyl, oxolanyl, fluorinated oxolanyl, C3-C5 cycloalkyl, fluorinated C3-C5 cycloalkyl, C3-C5 cycloalkoxy-C1-C4-alkyl and fluorinated C3-C5 cycloalkoxy-C1-C4-alkyl.本發明係關於新穎醯胺基環烷基化合物，具體而言係關於如本文所述式I化合物及其鹽及N-氧化物。該等化合物具有有價值之治療性質且具體而言適用於治療對多巴胺D3受體調節有反應之疾病。在式I中，變量具有以下含義：m 係1或2，n 係1或2，A 係選自由CH2、CH2CH2、CHFCH2及CF2CH2組成之群，R1 係氫或C1-C3-烷基，R2 係選自由氫及氟組成之群，R3a 係選自由氫及甲基組成之群，R3b 係選自由氫及甲基組成之群，R4 係具支鏈C4-C6烷基或具支鏈氟化C4-C6烷基，且R5 係含氧基團，例如C1-C2-烷氧基-C1-C4-烷基、氟化C1-C2-烷氧基-C1-C4-烷基、羥基-C1-C4-烷基、氟化羥基-C1-C4-烷基、氧雜環丁基、氟化氧雜環丁基、氧雜環戊基、氟化氧雜環戊基、C3-C5環烷基、氟化C3-C5環烷基、C3-C5環烷氧基-C1-C4-烷基及氟化C3-C5環烷氧基-C1-C4-烷基。
